The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative survival in metastatic castration-sensitive prostate cancer (mCSPC) by prognostic subgroups: A living network meta-analysis.
 
Syed Arsalan Ahmed Naqvi
No Relationships to Disclose
 
Irbaz Bin Riaz
No Relationships to Disclose
 
Kaneez Zahra Rubab Khakwani
No Relationships to Disclose
 
Arifa Bibi
No Relationships to Disclose
 
Jack R. Andrews
No Relationships to Disclose
 
Daniel S Childs
Employment - Mayo Clinic
Honoraria - International Centers for Precision Oncology Foundation; IntrinsiQ; MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Janssen Biotech (Inst); Novartis (Inst)
Research Funding - Janssen Biotech (Inst)
Travel, Accommodations, Expenses - Prostate Cancer Foundation
 
Praful Ravi
Research Funding - Bayer (Inst); Lilly (Inst); Telix Pharmaceuticals (Inst)
 
Jacob Orme
Consulting or Advisory Role - NaNotics
Patents, Royalties, Other Intellectual Property - Patents regarding PD-L1 cleavage and immunotherapy resistance in multiple cancers. (Inst)
 
Parminder Singh
Honoraria - Curio Science; Medpage/ASCO
Consulting or Advisory Role - AVEO; Bayer; EMD Serono; ImmunityBio; Janssen Oncology; Seattle Genetics/Astellas (Inst)
Research Funding - EMD Serono (Inst)
(OPTIONAL) Uncompensated Relationships - Seagen
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; Bayer; Bayer; Castle Biosciences; Horizon CME; Janssen; Janssen Oncology; Lilly; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals; Verity Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology (Inst); Pfizer; Pfizer (Inst); Phosplatin Therapeutics (Inst)